Thrombolytics (Clot-Busters): Dissolving Clots
Antiplatelets and anticoagulants can only stop a clot from GROWING. But when a clot has already choked off the brain in a stroke, or the heart in a massive attack, you need something that reaches in and DISSOLVES it. That's what clot-busters do — with breathtaking, life-restoring power, and a terrifying price: they can make you bleed anywhere, including into the brain. This is medicine's ultimate high-stakes gamble against the clock.
A woman's face droops, her speech slurs, her arm goes weak — an acute ischaemic stroke, a clot choking off part of her brain. 'Time is brain': every minute, millions of neurons die. If she reaches hospital fast enough and a scan rules out bleeding, the team gives a clot-busting drug that dissolves the blockage — and, sometimes, her symptoms melt away before your eyes. But the same drug can trigger catastrophic bleeding, so the decision is a razor-thin balance of enormous benefit against serious risk, made against the clock.
How clot-busters work
Thrombolytics activate the body's clot-dissolving system. The body has its own way to break down clots: an inactive protein called plasminogen is converted into plasmin, which chews apart the fibrin mesh that holds a clot together. Thrombolytic drugs — alteplase (tPA), tenecteplase, reteplase, and the older streptokinase — turbo-charge this conversion, generating a burst of plasmin that actively dissolves the existing clot. This is fundamentally different from the other antithrombotics: antiplatelets and anticoagulants only PREVENT new clotting, while thrombolytics REMOVE a clot that's already there. Their uses are the great emergencies of clotting: a major heart attack (STEMI) when angioplasty isn't available in time, an acute ischaemic stroke within the treatment window, and a massive, life-threatening pulmonary embolism.
Thrombolytics don't know which clot is 'good.' The plasmin they unleash dissolves the dangerous clot in the brain or heart — but it also breaks down the protective clots plugging any other injury in the body, which is why the great danger is bleeding, above all a catastrophic intracranial haemorrhage. This is why they have strict contraindications (recent surgery, active bleeding, a prior brain bleed, uncontrolled high blood pressure) and are strictly time-limited: their benefit is highest in the first hours and their bleeding risk never goes away. Every dose is a deliberate gamble — huge upside, serious downside.
- Thrombolytics convert plasminogen → plasmin, which dissolves the fibrin in an existing clot.
- They REMOVE clots — unlike antiplatelets/anticoagulants, which only prevent new ones.
- Drugs: alteplase (tPA), tenecteplase, reteplase, streptokinase.
- Uses: STEMI (if no PCI), acute ischemic stroke (in window), massive PE.
- Main risk: bleeding, especially intracranial hemorrhage; strict contraindications & time limits.
- Giving a thrombolytic without excluding bleeding (e.g., a brain scan in stroke). It could be fatal.
- Using it outside the time window. The benefit fades and the bleeding risk dominates.
- Ignoring contraindications (recent surgery, prior brain bleed, uncontrolled hypertension).
- Confusing 'dissolving a clot' (thrombolytics) with 'preventing a clot' (anticoagulants/antiplatelets).
What is the defining action of a thrombolytic drug?
- Thrombolytics convert plasminogen to plasmin, dissolving an existing clot's fibrin.
- They REMOVE clots (alteplase/tPA, streptokinase) — unlike thinners that only prevent them.
- Uses: STEMI (no PCI), acute ischemic stroke (in window), massive PE.
- Main risk is bleeding (especially intracranial); strict contraindications and time limits apply.
- Katzung BG. Basic & Clinical Pharmacology — Fibrinolytic (thrombolytic) drugs.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Fibrinolytic agents.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Fibrinolysis & thrombolytic drugs.
- AHA/ASA & ESC guidelines — Thrombolysis in stroke, STEMI & pulmonary embolism.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Thrombolytic drugs.
